ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?

MLA

Ushida, Yuta, et al. “ASO Author Reflections: What Are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?” Annals of Surgical Oncology, vol. 29, no. 8, Aug. 2022, pp. 5051–52. EBSCOhost, https://doi.org/10.1245/s10434-022-11621-1.

APA

Ushida, Y., Inoue, Y., Oba, A., Mie, T., Ito, H., Ono, Y., Sato, T., Ozaka, M., Sasaki, T., Saiura, A., Sasahira, N., & Takahashi, Y. (2022). ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy? Annals of Surgical Oncology, 29(8), 5051–5052. https://doi.org/10.1245/s10434-022-11621-1

Chicago

Ushida, Yuta, Yosuke Inoue, Atsushi Oba, Takafumi Mie, Hiromichi Ito, Yoshihiro Ono, Takafumi Sato, et al. 2022. “ASO Author Reflections: What Are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?” Annals of Surgical Oncology 29 (8): 5051–52. doi:10.1245/s10434-022-11621-1.